Literature DB >> 26552385

Association between the growth rate of subependymal giant cell astrocytoma and age in patients with tuberous sclerosis complex.

Jeng-Dau Tsai1,2, Chang-Ching Wei3,4, Teng-Fu Tsao1,5, Yu-Ping Hsiao1,6, Henry J Tsai7, Sheng-Hui Yang8, Min-Ling Tsai1,9, Ji-Nan Sheu10,11.   

Abstract

PURPOSE: The most common neurological complications associated with tuberous sclerosis complex (TSC) include intractable seizures that begin in infancy and subependymal giant cell astrocytoma (SEGA) complicated by hydrocephalus with increasing age. Information on SEGA growth of TSC patients is limited. This study aimed to examine the TSC-SEGA growth rates by periodic neuroimaging.
METHODS: This study evaluated the TSC-SEGA growth rates by serial neuroimaging. Fifty-eight patients with TSC underwent systematic evaluation, including a review of medical history and serial brain neuroimaging.
RESULTS: While magnetic resonance imaging was more sensitive in detecting cortical tubers than computed tomography (73.1 vs. 0 %, p < 0.001), its efficacy in identifying intracranial lesions was comparable to that of computed tomography (96.2 vs. 100 %, p = 0.658). Significant tumor growth was observed in children (p = 0.012) and adults (p = 0.028) during follow-up periods, respectively (median for children 23.5 months, interquartile range 18-40 months and median for adults 23 months, interquartile range 12-34 months). Further, the SEGA growth rate in children was significantly higher than that in adults (75.6 vs. 16.5 %, p = 0.03).
CONCLUSIONS: The results of the study show that SEGA has a significantly higher growth rate in children using serial follow-up brain imaging, suggesting the importance of performing follow-up neuroimaging at yearly intervals in childhood to identify and prevent potential comorbidities.

Entities:  

Keywords:  Magnetic resonance imaging; Neuroimaging; Subependymal giant cell astrocytoma; Tuberous sclerosis complex

Mesh:

Substances:

Year:  2015        PMID: 26552385     DOI: 10.1007/s00381-015-2947-4

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  25 in total

1.  Association between the growth rate of renal cysts/angiomyolipomas and age in the patients with tuberous sclerosis complex.

Authors:  Jeng-Dau Tsai; Chang-Ching Wei; Shan-Ming Chen; Ko-Huang Lue; Ji-Nan Sheu
Journal:  Int Urol Nephrol       Date:  2014-03-30       Impact factor: 2.370

2.  The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management.

Authors:  John R W Yates; Cathy Maclean; J Nicholas P Higgins; Ayla Humphrey; Kate le Maréchal; Michelle Clifford; Iris Carcani-Rathwell; Julian R Sampson; Patrick F Bolton
Journal:  Arch Dis Child       Date:  2011-08-03       Impact factor: 3.791

Review 3.  The diverse clinical manifestations of tuberous sclerosis complex: a review.

Authors:  Tena Rosser; Ashok Panigrahy; William McClintock
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

4.  Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs.

Authors:  Brigid A Staley; Emily A Vail; Elizabeth A Thiele
Journal:  Pediatrics       Date:  2010-12-20       Impact factor: 7.124

5.  MRI spectrum of cortical malformations in tuberous sclerosis complex.

Authors:  C Christophe; T Sékhara; F Rypens; F Ziereisen; F Christiaens; B Dan
Journal:  Brain Dev       Date:  2000-12       Impact factor: 1.961

Review 6.  Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review.

Authors:  Lindsay Hallett; Talia Foster; Zhimei Liu; Marissa Blieden; Joice Valentim
Journal:  Curr Med Res Opin       Date:  2011-06-21       Impact factor: 2.580

7.  Tuberous sclerosis complex associated with heterotopic ossification in a young girl.

Authors:  Teck-King Tan; Fong-Lin Chen; Ji-Nan Sheu; Shan-Ming Chen; Hsin-Hui Huang; Jeng-Dau Tsai
Journal:  Pediatr Neonatol       Date:  2013-02-04       Impact factor: 2.083

8.  Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.

Authors:  Jonathan Roth; E Steve Roach; Ute Bartels; Sergiusz Jóźwiak; Mary Kay Koenig; Howard L Weiner; David N Franz; Henry Z Wang
Journal:  Pediatr Neurol       Date:  2013-10-15       Impact factor: 3.372

Review 9.  CT and MR imaging of cerebral tuberous sclerosis.

Authors:  Y Inoue; Y Nemoto; R Murata; T Tashiro; M Shakudo; K Kohno; O Matsuoka; K Mochizuki
Journal:  Brain Dev       Date:  1998-06       Impact factor: 1.961

10.  Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.

Authors:  Darcy A Krueger; Hope Northrup
Journal:  Pediatr Neurol       Date:  2013-10       Impact factor: 3.372

View more
  3 in total

1.  Late Manifestation of Subependymal Giant Cell Astrocytoma With Hydrocephalus in an Adult Patient With Tuberous Sclerosis Complex.

Authors:  Sarah Zaher Addeen; Lilyan Bou Yehia; Lubna Aburas; Mhd Firas Safadi
Journal:  Cureus       Date:  2022-08-26

2.  Trends in survival and treatment of SEGA: National Cancer Database Analysis.

Authors:  James S Ryoo; Syed I Khalid; Anisse N Chaker; Mandana Behbahani; Ravi S Nunna; Ankit I Mehta
Journal:  Neurooncol Pract       Date:  2020-09-28

3.  Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study.

Authors:  Anna C Jansen; Elena Belousova; Mirjana P Benedik; Tom Carter; Vincent Cottin; Paolo Curatolo; Lisa D'Amato; Guillaume Beaure d'Augères; Petrus J de Vries; José C Ferreira; Martha Feucht; Carla Fladrowski; Christoph Hertzberg; Sergiusz Jozwiak; John A Lawson; Alfons Macaya; Ruben Marques; Rima Nabbout; Finbar O'Callaghan; Jiong Qin; Valentin Sander; Matthias Sauter; Seema Shah; Yukitoshi Takahashi; Renaud Touraine; Sotiris Youroukos; Bernard Zonnenberg; John C Kingswood
Journal:  Front Neurol       Date:  2019-08-02       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.